Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.

Clomipramine is a potent serotonin reuptake blocker that decreases the symptoms of obsessive-compulsive disorder (OCD). To investigate whether clomipramine treatment in OCD affects brain serotonergic responsiveness, metachlorophenylpiperazine (mCPP), a selective serotonin agonist, and placebo were given under double-blind conditions to nine patients with OCD before and after treatment with clomipramine. Unlike our previous observations of a marked transient increase in obsessional symptoms and anxiety following 0.5 mg/kg of mCPP, readministration of mCPP after four months of treatment with clomipramine did not significantly increase obsessional symptoms and anxiety. Similarly, the hyperthermic effect of mCPP observed before treatment was eliminated after treatment with clomipramine. These findings are consistent with the development of adaptive subsensitivity to the serotonergic agonist mCPP during clomipramine treatment. A similar alteration in the response to endogenous serotonin may mediate clomipramine's antiobsessional effects.

[1]  T. Insel,et al.  Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. , 1987, Archives of general psychiatry.

[2]  T. Insel,et al.  Drug treatment of obsessive-compulsive disorder. , 1987, Journal of affective disorders.

[3]  T. Insel,et al.  Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology , 1987, Biological Psychiatry.

[4]  T. Dawson,et al.  Receptor alterations associated with serotonergic agents: an autoradiographic analysis. , 1987, The Journal of clinical psychiatry.

[5]  J. Rapoport,et al.  Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. , 1987, Archives of general psychiatry.

[6]  D. Murphy,et al.  Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans. , 1985, The Journal of clinical endocrinology and metabolism.

[7]  M Linnoila,et al.  Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. , 1985, Archives of general psychiatry.

[8]  D. Beidel,et al.  Fluoxetine treatment of obsessive-compulsive disorder. , 1985, Journal of clinical psychopharmacology.

[9]  G. Chouinard,et al.  Antiobsessive effect of fluoxetine. , 1985, American Journal of Psychiatry.

[10]  R. Ganguli,et al.  Lymphocyte sensitivity to glucocorticoids. , 1985, American Journal of Psychiatry.

[11]  W. Stremmel,et al.  Conversion of androgens to estrogens in idiopathic hemochromatosis: comparison with alcoholic liver cirrhosis. , 1985, The Journal of clinical endocrinology and metabolism.

[12]  J. Volavka,et al.  Clomipramine and imipramine in obsessive-compulsive disorder , 1985, Psychiatry Research.

[13]  H. Westenberg,et al.  Zimeldine treatment of obsessive‐compulsive disorder , 1984, Acta psychiatrica Scandinavica.

[14]  A. Prasad.  A Double Blind Study of Imipramine versus Zimelidine in Treatment of Obsessive Compulsive Neurosis , 1984, Pharmacopsychiatry.

[15]  T. Insel,et al.  Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. , 1984, Life sciences.

[16]  D. Murphy,et al.  Long-term clorgyline treatment antagonizes the eating and motor function responses to m-chlorophenylpiperazine. , 1983, European journal of pharmacology.

[17]  T. Insel,et al.  Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. , 1983, Archives of general psychiatry.

[18]  R. Samanin,et al.  Effects of m-chlorophenylpiperazine on receptor binding and brain metabolism of monoamines in rats , 1981, Neurochemistry International.

[19]  A. Quattrone,et al.  Pharmacological evidence of supersensitivity of central serotonergic receptors involved in the control of prolactin secretion. , 1981, European journal of pharmacology.

[20]  R. Fuller,et al.  Disposition and pharmacological effects of m-Chlorophenylpiperazine in rats , 1981, Neuropharmacology.

[21]  J. Ananth,et al.  Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. , 1981, Progress in neuro-psychopharmacology.

[22]  M. Åsberg,et al.  Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. , 1980, Archives of general psychiatry.

[23]  M. Åsberg,et al.  Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. , 1980, Archives of general psychiatry.

[24]  L. Antkiewicz-Michaluk,et al.  5‐Hydroxytryptamine‐like properties of m‐chlorophenylpiperazine: comparison with quipazine , 1980, The Journal of pharmacy and pharmacology.

[25]  A. Lewandowska,et al.  Central serotoninmimetic action of phenylpiperazines. , 1980, Polish journal of pharmacology and pharmacy.

[26]  R. Fuller,et al.  Structural relationships in the inhibition of [(3)H]serotonin binding to rat brain membranes in vitro by 1-phenyl-piperazines. , 1980, Biochemical Pharmacology.

[27]  I. Marks,et al.  Clomipramine and Exposure for Obsessive-Compulsive Rituals: 1 , 1980, British Journal of Psychiatry.

[28]  Luscombe Dk,et al.  Some pharmacological aspects of desmethylclomipramine. , 1980 .

[29]  S. B. Ross,et al.  Inhibition of the neuronal uptake of 5-hydroxytryptamine and noradrenaline in rat brain by (Z)- and (E)-3-(4-Bromophenyl)-N,N-dimethyl-3-(3-pyridyl) allylamines and their secondary analogues , 1977, Neuropharmacology.

[30]  E. N. Cole,et al.  Plasma prolactin concentrations in patients on clomipramine. , 1976, Postgraduate medical journal.

[31]  W. Daughaday,et al.  Prolactin response to thyrotropin releasing hormone in normal subjects. , 1973, The Journal of clinical endocrinology and metabolism.